HIGH RATE OF MORBID CENTRAL LINE ASSOCIATED COMPLICATIONS DURING TREATMENT WITH DOSE‐ADJUSTED R‐EPOCH THERAPY FOR NON‐HODGKIN LYMPHOMA. (June 2017) - Reagan, P.; David, R.; Baran, A.; Kelly, J.; Loh, K.; Casulo, C.; Barr, P.; Friedberg, J.